The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NoLEEta: No chemotherapy in intermediate-risk HR+ HER2- early breast cancer treated with ribociclib in the adjuvant setting—A non-inferiority phase III trial.
 
Francois Clement Bidard
Consulting or Advisory Role - AstraZeneca; Carrick Pharm; Daiichi-Sankyo; Hengrui Pharmaceutical ; Inatherys; Lilly; Menarini Silicon Biosystems; Novartis; Pfizer; Relay Tx; Roche; Tempus
Speakers' Bureau - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Roche
Research Funding - GE Healthcare (Inst); Menarini Silicon Biosystems (Inst); Merck KGaA (Inst); MSD (Inst); Natera (Inst); Novartis (Inst); Personalis (Inst); Pfizer (Inst); Prolynx (Inst); Roche (Inst); SAGA Dx (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - ESR1 & MSI detection techniques (patents) (Inst); Prognosis assessment by a digital pathology assay in early breast cancer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi-Sankyo; Novartis; Pfizer; Roche
 
Thomas Bachelot
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; pfizer; Roche
 
Alexia Savignoni
No Relationships to Disclose
 
Jerome Martin Babau
Honoraria - Amgen; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; GlaxoSmithKline; Lilly; MSD Oncology; Novartis; Pfizer
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer
 
Gustavo Werutsky
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; BeiGene; Daiichi Sankyo/Astra Zeneca; MSD; Novartis; Olema Oncology; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Libbs (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Madhumita Manna
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Merck/Pfizer; Novartis Canada Pharmaceuticals Inc; Pfizer; Roche Canada
Speakers' Bureau - AstraZeneca Canada; Gilead Sciences; Knight Therapeutics; Lilly; Merck; Novartis Canada Pharmaceuticals Inc; Pfizer
Research Funding - AstraZeneca Canada (Inst); AstraZeneca Canada (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Pfizer
 
Mattea Reinisch
Honoraria - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Pfizer; Roche Pharma AG; Seagen; SOMATEX; Stemline Therapeutics
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Seagen; Somatex
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Daiichi Sankyo Europe GmbH; Novartis; Pfizer; Roche Pharma AG; Stemline Therapeutics
 
Lucia Del Mastro
Honoraria - Gilead Sciences; Lilly; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Ipsen; Lilly; Menarini; MSD; Novartis; Olema Oncology; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Olema Oncology; Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Menarini Group; Pfizer; Roche
 
Judith Kroep
Consulting or Advisory Role - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Philips Research (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH (Inst)
 
Elena Galve Calvo
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; MSD; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer
 
Estelle Roux
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Wendy Parulekar
No Relationships to Disclose
 
Sibylle Loibl
Employment - GBG Forschungs; Goethe Universität / Universitätsklinikum Frankurt/Main
Consulting or Advisory Role - Abbvie (Inst); American Institute of Continuing Medical Education (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BMS (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Lilly (Inst); Menarini Group (Inst); MICE ideas (Inst); MSD Oncology (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Speakers' Bureau - Agendia (Inst); AstraZeneca (Inst); Bayer (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Medscape (Inst); Menarini Group (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Streamedup! (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Greenwich LifeSciences (Inst); Menarini Group (Inst); MolecularHealth (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Digital Ki67 Evaluator, VM Scope GmbH (Inst); Patent Issued EP15702464.7 (Inst); Patent Pending EP14153692.0 (Inst); Patent Pending EP19808852.8 (Inst); Patent Pending EP21152186.9 (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Gilead Sciences (Inst); MSD (Inst); Roche (Inst)
 
Leonardo Rodrigues
No Relationships to Disclose
 
A. Elise Van Leeuwen-Stok
No Relationships to Disclose
 
Karin Rothgiesser
No Relationships to Disclose
 
Mafalda Oliveira
Honoraria - AstraZeneca; Curio Science; Gilead Sciences; i-One; Lilly; MSD
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; ProteinQure; Roche
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); Immutep (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Gilead Sciences; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - President elected, SOLTI Cancer Research Group
 
Sylvie Mijonnet
No Relationships to Disclose
 
Sandrine Marques
No Relationships to Disclose
 
Jose Sandoval
Expert Testimony - AstraZeneca; Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Pfizer